阿爾法企業(00948.HK)獲蒙牛貝拉米產品中澳分銷權
阿爾法企業(00948.HK)公佈,與貝拉米有機食品訂立一份分銷協議,以及與Bellamy's Organic Pty Ltd (貝拉米澳洲) 訂立另一份分銷協議,公司附屬將被委任爲分銷商,獲中國及澳洲分銷權,爲期12個月。
公告稱,貝拉米於2019年被蒙牛(02319.HK)收購,爲蒙牛於2020年財政年度貢獻超過10億人民幣收入,貝拉米主要產品包括有機嬰兒配方奶粉及有機嬰兒米粉。董事相信,通過擴大銷售及╱或分銷奶粉及嬰兒食品品牌的數量,集團的產品將更多元化,並有利於奶類產品業務的表現,將爲集團的財務業績帶來正面貢獻,併爲股東價值帶來提升潛力。(me/a)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.